JCI Insight (Jul 2023)

The MIF promoter SNP rs755622 is associated with immune activation in glioblastoma

  • Tyler J. Alban,
  • Matthew M. Grabowski,
  • Balint Otvos,
  • Defne Bayik,
  • Wesley Wang,
  • Ajay Zalavadia,
  • Vlad Makarov,
  • Katie Troike,
  • Mary McGraw,
  • Anja Rabljenovic,
  • Adam Lauko,
  • Chase Neumann,
  • Gustavo Roversi,
  • Kristin A. Waite,
  • Gino Cioffi,
  • Nirav Patil,
  • Thuy T. Tran,
  • Kathleen McCortney,
  • Alicia Steffens,
  • C. Marcela Diaz,
  • J. Mark Brown,
  • Kathleen M. Egan,
  • Craig M. Horbinski,
  • Jill S. Barnholtz-Sloan,
  • Prajwal Rajappa,
  • Michael A. Vogelbaum,
  • Richard Bucala,
  • Timothy A. Chan,
  • Manmeet S. Ahluwalia,
  • Justin D. Lathia

Journal volume & issue
Vol. 8, no. 13

Abstract

Read online

Intratumoral heterogeneity is a defining hallmark of glioblastoma, driving drug resistance and ultimately recurrence. Many somatic drivers of microenvironmental change have been shown to affect this heterogeneity and, ultimately, the treatment response. However, little is known about how germline mutations affect the tumoral microenvironment. Here, we find that the single-nucleotide polymorphism (SNP) rs755622 in the promoter of the cytokine macrophage migration inhibitory factor (MIF) is associated with increased leukocyte infiltration in glioblastoma. Furthermore, we identified an association between rs755622 and lactotransferrin expression, which could also be used as a biomarker for immune-infiltrated tumors. These findings demonstrate that a germline SNP in the promoter region of MIF may affect the immune microenvironment and further reveal a link between lactotransferrin and immune activation.

Keywords